Gabriela Kłodowska-Duda

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Davina J. Hensman Moss, Antonio F. Pardiñas, Douglas R. Langbehn et al. · The Lancet Neurology · 2017 · 332 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 142 citations · Full text

Life Sciences, Immunology, Neurology +17

Large-scale replication and heterogeneity in Parkinson disease genetic loci

Manu Sharma, John P. A. Ioannidis, Jan Aasly et al. · Neurology · 2012 · 132 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17